Todd Grinnell MD

Todd Grinnell is Senior Director, Medical Affairs, Neuro and Pain at Sunovion, where he is the Medical Affairs lead for the epilepsy products portfolio. In this role, Mr. Grinnell is actively involved in exploration of digital health technologies in post-marketing clinical research, including the use of wearable device technology to assess objective clinical endpoints and the extent to which novel physiological data may provide complementary evidence of both objective and subjective responses to therapeutic intervention.

Mr. Grinnell is keenly interested in the current and potential future role of various digital health technologies in providing a more comprehensive assessment of the role of Sunovion’s medications in contributing to better overall management of chronic medical conditions in the therapeutic areas of neurology and psychiatry. He also contributes to the evaluation of potential new products and sourcing of novel technologies to enhance the development of those products. Todd has worked in the pharmaceutical industry for over 20 years in rolls as diverse as Discovery Research and Translational Medicine as well as Clinical Development and Medical Affairs. He received an AB in biochemistry from Harvard University with additional graduate work in molecular biology and neuroscience.